Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alkindi Sprinkle is a pediatric-specific, immediate-release oral formulation of hydrocortisone, a synthetic glucocorticoid. It is indicated as replacement therapy for adrenocortical insufficiency in infants, children, and adolescents from birth to 17 years of age. Hydrocortisone acts by mimicking endogenous cortisol, exerting metabolic effects and modulating immune responses. The granular formulation allows for precise low-dose titration and easy administration by sprinkling on food or directly into the mouth—addressing challenges with dosing accuracy in young children who cannot swallow tablets. Alkindi Sprinkle is the first FDA-approved granular hydrocortisone product specifically designed for pediatric use[1][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alkindi Sprinkle.